Victory Capital Management Inc. raised its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 7.1% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 13,676 shares of the medical instruments supplier’s stock after buying an additional 902 shares during the period. Victory Capital Management Inc.’s holdings in Becton, Dickinson and were worth $2,509,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the stock. Empire Life Investments Inc. acquired a new stake in Becton, Dickinson and during the fourth quarter valued at $13,383,000. LeJeune Puetz Investment Counsel LLC acquired a new stake in Becton, Dickinson and during the fourth quarter valued at $1,031,000. IFM Investors Pty Ltd acquired a new stake in Becton, Dickinson and during the fourth quarter valued at $480,000. Pittenger & Anderson Inc. boosted its stake in Becton, Dickinson and by 2.0% in the fourth quarter. Pittenger & Anderson Inc. now owns 43,090 shares of the medical instruments supplier’s stock valued at $7,134,000 after buying an additional 845 shares during the last quarter. Finally, Thrivent Financial for Lutherans boosted its stake in Becton, Dickinson and by 5.7% in the fourth quarter. Thrivent Financial for Lutherans now owns 8,185 shares of the medical instruments supplier’s stock valued at $1,357,000 after buying an additional 440 shares during the last quarter. 75.71% of the stock is currently owned by hedge funds and other institutional investors.

Becton, Dickinson and Company (NYSE BDX) traded up 0.40% during midday trading on Monday, reaching $197.84. The company’s stock had a trading volume of 957,775 shares. Becton, Dickinson and Company has a 12-month low of $161.29 and a 12-month high of $206.63. The firm has a market cap of $42.20 billion, a price-to-earnings ratio of 32.86 and a beta of 1.05. The company’s 50-day moving average is $197.67 and its 200 day moving average is $186.53.

Becton, Dickinson and (NYSE:BDX) last released its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 EPS for the quarter, beating analysts’ consensus estimates of $2.44 by $0.02. The firm had revenue of $3.04 billion for the quarter, compared to analysts’ expectations of $3.06 billion. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. The company’s quarterly revenue was down 5.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.35 earnings per share. Equities analysts forecast that Becton, Dickinson and Company will post $9.46 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 29th. Stockholders of record on Friday, September 8th will be paid a dividend of $0.73 per share. The ex-dividend date of this dividend is Thursday, September 7th. This represents a $2.92 dividend on an annualized basis and a dividend yield of 1.48%. Becton, Dickinson and’s dividend payout ratio is 83.43%.

ILLEGAL ACTIVITY NOTICE: “Victory Capital Management Inc. Has $2.51 Million Position in Becton, Dickinson and Company (NYSE:BDX)” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/08/07/victory-capital-management-inc-increases-stake-in-becton-dickinson-and-company-nysebdx-updated-updated-updated.html.

Several analysts have weighed in on BDX shares. Zacks Investment Research raised Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $206.00 price target on the stock in a report on Tuesday, April 11th. Royal Bank Of Canada reiterated a “hold” rating and set a $177.00 price objective on shares of Becton, Dickinson and in a research report on Thursday, April 13th. Evercore ISI upgraded Becton, Dickinson and from an “in-line” rating to an “outperform” rating and increased their price objective for the company from $186.00 to $200.00 in a research report on Monday, April 24th. Raymond James Financial, Inc. upgraded Becton, Dickinson and from an “outperform” rating to a “strong-buy” rating and reduced their price objective for the company from $210.00 to $180.00 in a research report on Friday, June 30th. Finally, Cowen and Company reiterated an “outperform” rating and set a $230.00 price objective (up from $200.00) on shares of Becton, Dickinson and in a research report on Monday, July 10th. One investment analyst has rated the stock with a sell rating, five have given a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $194.69.

In other news, VP Jeffrey S. Sherman sold 28,765 shares of the company’s stock in a transaction that occurred on Thursday, May 25th. The stock was sold at an average price of $185.98, for a total transaction of $5,349,714.70. Following the transaction, the vice president now owns 70,821 shares of the company’s stock, valued at $13,171,289.58. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 1.40% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Stock Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related stocks with our FREE daily email newsletter.